Loading...
•
Mar 31
•/
Nyxoah SA Q1 2025 Earnings Report
Nyxoah reported increased operating loss in Q1 2025 due to scale-up and commercialization efforts despite steady revenue.
Key Takeaways
Nyxoah recorded €1.1 million in revenue for Q1 2025, slightly below last year. The company's operating loss widened to €20.6 million as it ramped up expenses in preparation for the U.S. commercialization of its Genio® system. With the FDA approval process nearing completion, Nyxoah maintained a strong cash position to support its strategic objectives.
Revenue reached €1.1 million, a slight decline from Q1 2024.
Operating loss increased to €20.6 million due to commercialization and R&D expenses.
Cash and financial assets totaled €63.0 million at quarter-end.
Company anticipates FDA approval for Genio® system in Q2 2025.
Nyxoah SA
Nyxoah SA
Nyxoah SA Revenue by Segment
Revenue by Segment
Genio System Sales Revenue
CapyFin.com Forward Guidance
Nyxoah remains focused on receiving FDA approval in Q2 2025 and preparing for the Genio® system’s U.S. commercial launch.
Positive Outlook
- FDA Approvable Letter received for Genio® system.
- Final validation work for FDA requirements completed.
- Manufacturing site already passed prior FDA inspection.
- Strong cash position supports upcoming commercialization.
- Increased R&D spending aimed at product advancement.
Challenges Ahead
- Operating loss widened significantly compared to Q1 2024.
- Revenue declined slightly year-over-year.
- Cash and financial assets decreased from €85.6M to €63.0M.
- High SG&A expenses due to commercialization preparations.
- Continued negative net income impacts financial position.